Clinical Trials
537
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (375 trials with phase data)• Click on a phase to view related trials
Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365')
- Conditions
- Weight Loss
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 144
- Registration Number
- NCT07195708
Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control
- Conditions
- Chronic PainIntractable PainChronic Leg PainLow Back PainChronic Low-back PainLeg Pain
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT07190807
RESCUE: Discontinuation of GLP-1
- Conditions
- Obesity
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT07190794
- Locations
- 🇺🇸
Bariendo, Miramar, Florida, United States
🇺🇸Brigham & Women's Hospital, Boston, Massachusetts, United States
PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)
- Conditions
- Persistent Atrial Fibrillation
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 640
- Registration Number
- NCT07106970
- Locations
- 🇨🇳
Beijing Anzhen Hospital, affiliated to Capital Medical University, Beijing, China
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
- Conditions
- Heart Failure - NYHA II - IV
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- Boston Scientific Corporation
- Target Recruit Count
- 850
- Registration Number
- NCT07069738
- Prev
- 1
- 2
- 3
- 4
- 5
- 102
- Next
News
Boston Scientific Acquires Elutia's BioEnvelope Business for $88 Million, Fueling Breast Reconstruction Pipeline
Elutia Inc. has entered into a definitive agreement to sell its EluPro™ and CanGaroo® bioenvelopes to Boston Scientific Corporation for $88 million in cash, with the deal expected to close in Q4 2025.
VIVA24: Late-Breaking Trials Highlight Advances in Vascular Intervention
The PROMISE II trial demonstrates sustained limb salvage and wound healing at 2 years using the LimFlow System for no-option CLTI patients.
VIVA24: Late-Breaking Trials Highlight Advances in Peripheral Artery Disease Treatment
The PROMISE II trial demonstrates sustained limb salvage and wound healing at two years using the LimFlow System for no-option CLTI patients.
VIVA24: Novel Therapies Show Promise in Vascular Disease Treatment
• The Esprit BTK scaffold demonstrated superior long-term outcomes in treating chronic limb-threatening ischemia compared to percutaneous transluminal angioplasty. • Shockwave Javelin Peripheral IVL catheter met efficacy and safety goals, significantly reducing stenosis in severely calcified lesions. • TCAR using the ENROUTE system proves safe and effective for carotid stenosis in standard-surgical-risk patients, with low stroke and cranial nerve injury rates.
Senseonics' Eversense 365 CGM System Receives FDA Clearance for One-Year Use
Senseonics and Ascensia Diabetes Care secured FDA clearance for Eversense 365, a next-generation continuous glucose monitoring (CGM) system, for adults with type 1 and type 2 diabetes.